Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
LQDA - Liquidia Corp
-0.07(-1.67%)6:00:01 PM 11/26/2021
Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company. The company focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its product candidates include LIQ861 for the treatment of pulmonary arterial hypertension; and LIQ865 for the treatment of local post-operative pain. The company also provides strategy, investment, and commercialization services for rare disease pharmaceutical products, such as generic Remodulin, a parenteral formulation of treprostinil for pulmonary arterial hypertension. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics


Related Peers

Stock news

    Liquidia Corporation (NASDAQ:LQDA) insiders placed bullish bets worth US$1.6m in the last 12 months

    In the last year, multiple insiders have substantially increased their holdings of Liquidia Corporation ( NASDAQ:LQDA...

    Liquidia to Participate in the Jefferies London Healthcare Conference

    MORRISVILLE, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer of Liquidia, will provide an update on the company's business during a fireside chat at the Jefferies 2021 Virtual London Healthcare Conference being held November 16-19, 2021 . The fireside chat will be available to registered participants on-demand beginning at 8:00 a.m. GMT on November 18, 2021. A webcast of the event will be available on th

    Notable Liquidia Insider Makes $495K Buy

    Russell Schundler, Insider at Liquidia (NASDAQ:LQDA), made a large insider buy on November 10, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Schundler purchased 117,908 shares of Liquidia at at prices ranging from $4.18 to $4.28. The total transaction amounted to $496,834. Following the transaction, Schundler now owns 235,088 shares of the company, worth $1,123,720. Liquidia shares are trading up 13.0% at $

    4 Penny Stocks Insiders Are Buying

    When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Calithera Biosciences The Trade: Calithera Biosciences, Inc. (NASDAQ: CALA) Director Jonathan G Drachman acquired a total

    Morrisville firm gets tentative approval for hypertension treatment, but lawsuit still a hurdle

    The FDA has granted tentative approval of a Morrisville-based drugmaker's treatment for pulmonary arterial hypertension, but a lawsuit is keeping the company from marketing the drug.

    Liquidia's Inhaled Treprostinil Powder Scores Tentative FDA Approval For PAH

    The FDA has granted tentative approval to Liquidia Corporation's (NASDAQ: LQDA) Yutrepia (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. Tentative approval indicates that Yutrepia has met all regulatory standards for quality, safety, and efficacy required for approval in the U.S. Due to a regulatory stay according to the Drug Price Competition and Pate

    FDA Grants Tentative Approval for Liquidia’s YUTREPIA™ (Treprostinil) Inhalation Powder

    First dry-powder formulation of treprostinil to meet criteria required for FDA approvalFinal FDA approval may occur in October 2022 or earlier upon resolution of on-going litigationConference call and webcast scheduled for today at 9:00 a.m. Eastern Standard Time MORRISVILLE, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder, previou